文献速递放疗物理与技术姑息放疗与转移瘤

Medicare Advantage计划中对放射治疗的不当拒绝

Inappropriate Denials for Radiation Therapy in Medicare Advantage Plans.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-11-16

该分析利用CMS公开的2022年至2024年6月上诉裁决数据,比较放射治疗服务与所有健康服务的不当拒绝率。结果显示放射治疗服务的不当拒绝率在2022、2023、2024年分别为15.04%、18.69%、16.01%,均显著高于所有健康服务的4.69%、5.28%、3.44%(所有P值<.00001)。

要点

  • 2022年至2024年6月,放射治疗上诉中不当拒绝率为17.39%(274/1576),所有健康服务为4.66%(20195/433788),差异有统计学意义(P<.00001)。
  • 按关键词分析,近距离治疗、立体定向体部放疗、质子治疗和调强放疗的不当拒绝率分别为12.75%、26.11%、13.02%和41.06%。
  • 前列腺癌质子治疗上诉的不当拒绝率特别低,为3.45%;乳腺癌调强放疗上诉的不当拒绝率特别高,为82.14%。

核心结论

  • Medicare Advantage计划对放射治疗服务的不当拒绝率高于非放射治疗服务。
  • 这些数据需要紧急政策改变,以防止符合Medicare资格的患者被不当拒绝获得癌症治疗。

研究设计与样本

  • 分析来自CMS网站上诉裁决搜索的2022年至2024年6月数据,数据包含第三方独立审查实体使用Medicare覆盖指南判定拒绝适当性的裁决。
  • 计算放射治疗服务和所有健康服务的不当拒绝百分比,使用卡方检验比较两组不当拒绝水平,并按关键词和疾病过滤分析治疗模式和诊断趋势。

主要发现

  • 放射治疗服务不当拒绝率在2022、2023、2024年分别为15.04%、18.69%、16.01%,所有健康服务分别为4.69%、5.28%、3.44%。
  • 自2022年以来,放射治疗上诉中不当拒绝274/1576(17.39%),所有健康服务上诉中不当拒绝20195/433788(4.66%),所有3年及整个时间段差异均有统计学意义(所有P值<.00001)。
  • 使用关键词近距离治疗、立体定向体部放疗、质子治疗和调强放疗,2022年至2024年不当拒绝率分别为12.75%、26.11%、13.02%和41.06%。
  • 前列腺癌质子治疗上诉的不当拒绝率特别低,为3.45%;乳腺癌调强放疗上诉的不当拒绝率特别高,为82.14%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation oncologists are known to be burdened with prior authorization and insurance denials more than other medical specialties. This analysis sought to use publicly available data and determine whether Medicare Advantage plans are inappropriately denying radiation therapy (RT) services more than other health services. METHODS AND MATERIALS: Data from the Appeals Decision Search on the Centers for Medicare & Medicaid Services website were extracted from 2022 through June 2024. The data contain appeal decisions from a third-party independent review entity, which uses Medicare coverage guidelines to determine the appropriateness of a denial. Percentages of inappropriate denials were calculated for RT services and all health services. A chi-square test was used to compare inappropriate denial levels between RT and everything else. Decisions were also filtered by "keyword" and "condition" to analyze trends in treatment modalities and diagnosis, respectively. RESULTS: RT services were inappropriately denied in 15.04%, 18.69%, and 16.01% of cases for 2022, 2023, and 2024, respectively, while inappropriate denials for all health services were only 4.69%, 5.28%, and 3.44%, respectively. Overall, since 2022, 274 out of 1576 RT appeals were inappropriately denied (17.39%), while only 20,195 out of 433,788 total appeals were inappropriately denied for all health services (4.66%). The difference was statistically significant for all 3 years and for the entire time period, with all P values < .00001. Using keywords brachytherapy, stereotactic body radiation therapy, proton, and intensity-modulated RT, inappropriate denial rates varied at 12.75%, 26.11%, 13.02%, and 41.06%, respectively, from 2022 to 2024. Prostate cancer appeals for protons had particularly low rates of inappropriate denial at 3.45%, while breast cancer appeals for intensity-modulated RT had particularly high rates of inappropriate denial at 82.14%. CONCLUSIONS: Medicare Advantage plans are inappropriately denying RT services more than non-RT services. These data warrant urgent policy changes to prevent Medicare-eligible patients from being inappropriately denied access to cancer treatments.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Pasetsky J, Bhatt K, Kachnic LA, et al. Inappropriate Denials for Radiation Therapy in Medicare Advantage Plans. Int J Radiat Oncol Biol Phys. 2024. PMID: 39551102. doi:10.1016/j.ijrobp.2024.11.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。